Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants

American Heart Journal

Volumn 199, Issue , 2018, Pages 170-175

  Theodorakis, Michael J ^a   Coleman, Ruth L ^a   Feng, Huimei ^a   Chan, Juliana ^b   Chiasson, Jean Louis ^c   Ge, Junbo ^d   Gerstein, Hertzel C ^e   Huo, Yong ^f   Lang, Zhihui ^g   McMurray, John J ^h   Rydén, Lars ⁱ   Schröder, Stefan ^j   Tendera, Michal ^k   Tuomilehto, Jaakko ^l,m,n,o   Yang, Wenying ^p   Hu, Dayi ^q   Pan, Changyu ^r   Holman, Rury R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d FUDAN UNIVERSITY   (China)

^e HAMILTON HEALTH SCIENCES   (Canada)

^f PEKING UNIVERSITY FIRST HOSPITAL   (China)

^g Bayer Pharma AG   (China)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^j BAYER AG   (Germany)

^k MEDICAL UNIVERSITY OF SILESIA   (Poland)

^l DANUBE UNIVERSITY KREMS   (Austria)

^m NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

ⁿ KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^o DASMAN DIABETES INSTITUTE   (Kuwait)

^p CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^q PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^r CHINESE PLA GENERAL HOSPITAL   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALANINE AMINOTRANSFERASE; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; GLYCOSIDASE INHIBITOR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ATRIAL FIBRILLATION; BODY MASS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; CLINICAL PROTOCOL; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; ESTIMATED GLOMERULAR FILTRATION RATE; EVALUATION STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; LETTER; LEUKOCYTE COUNT; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PLATELET COUNT; PRIORITY JOURNAL; RACE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK MANAGEMENT; STABLE ANGINA PECTORIS; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; UNSTABLE ANGINA PECTORIS; WAIST CIRCUMFERENCE; BLOOD; CARDIOVASCULAR DISEASE; COMPLICATION; GLUCOSE TOLERANCE TEST; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PROCEDURES;

ACARBOSE; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GLUCOSE TOLERANCE TEST; GLYCOSIDE HYDROLASE INHIBITORS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85032150802     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2017.09.001     Document Type: Letter

References (13)

1. Holman, R.R., Bethel, M.A., Chan, J.C.N., et al., for the ACE Study Group, Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. Am Heart J 168 (2014), 23–29.
2. Holman, Rury R., Bethel, Mary A., Chan, Juliana C.N., et al. Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. Int J Endocrinol Metab 36 (2016), 1–4.
3. Ma, Y.C., Zuo, L., Chen, J.H., Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 17 (2006), 2937–2944.
4. Chiasson, J.L., Josse, R.G., Gomis, R., et al., STOP-NIDDM Trial Research Group, Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359 (2002), 2072–2077.
5. Chiasson, J.L., Josse, R.G., Gomis, R., et al., the STOP-NIDDM Trial Research Group, Acarbose treatment and the risk of cardiovascular disease and hypertension in subjects with impaired glucose tolerance. The STOP-NIDDM trial. JAMA 290 (2003), 486–494.
6. Gerstein, H.C., Yusuf, S., Bosch, J., et al., on behalf of the DREAM trial investigators, Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 (2006), 1096–1105.
7. Krum, H., McMurray, J.J.V., Horton, E., et al. Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials. Cardiovasc Ther 28 (2010), 124–132.
8. Holman, R.R., Haffner, S.M., McMurray, J.J., et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 362 (2010), 1463–1476.
9. Gerstein, H.C., Bosch, J., Dagenais, G.R., et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. ORIGIN Trial Investigators. N Engl J Med 367 (2012), 319–328.
10. Hanefeld, M., Chiasson, J.L., Koehler, C., et al. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 35 (2004), 1073–1078.
11. Hanefeld, M., Cagatay, M., Petrowitsch, T., et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 25 (2004), 10–16.
12. Standl, E., Theodorakis, M.J., Erbach, M., et al. On the potential of acarbose to reduce cardiovascular disease. Cardiovasc Diabetol, 13, 2014, 81.
13. Asakura, M., Kim, J., Asanuma, H., et al. Does treatment of impaired glucose tolerance improve cardiovascular outcomes in patients with previous myocardial infarction?. Cardiovasc Drugs Ther, 2017, 10.1007/s10557-017-6740-3 [Epub ahead of print].